NCT01014520

Brief Summary

The hypothesis of this study is that Gabapentin or Amitriptyline has no role in preemptive analgesia to reduce postoperative pain after lumbar diskectomies.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started May 2009

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2009

Completed
7 months until next milestone

First Submitted

Initial submission to the registry

November 14, 2009

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 17, 2009

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2010

Completed
28 days until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2010

Completed
Last Updated

November 17, 2009

Status Verified

November 1, 2009

Enrollment Period

9 months

First QC Date

November 14, 2009

Last Update Submit

November 16, 2009

Conditions

Keywords

LumbarDiskectomyLaminectomy

Outcome Measures

Primary Outcomes (1)

  • 30% reduction in opium consumption in either study arms compared to the placebo group

    Within the first 24 hours after surgery

Secondary Outcomes (1)

  • 30% reduction in pain according to visual analogue scale in either study arms compared to the placebo group

    Within the first 24 hours after surgery

Study Arms (2)

Gabapentin

EXPERIMENTAL

Neurontin

Drug: Gabapentin , Amitriptyline

Amitriptyline

EXPERIMENTAL

Elavil

Drug: Gabapentin , Amitriptyline

Interventions

Capsule, 300 mg, oral, single dose 2 hours before surgery Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery

Also known as: Neurontin, Elavil
AmitriptylineGabapentin

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Signed Informed Consent
  • Age:18 to 60
  • Weight: 60 to 80 Kg
  • ASA Class: I,II
  • Concordant physical and imaging findings in favor of symptomatic lumbar disk herniation
  • Single level lumbar disk herniation unresponsive to medical treatment

You may not qualify if:

  • Previous consumption of Gabapentin or Amitriptyline
  • Known allergy to investigated drugs
  • Reluctant to sign informed consent
  • Previous history of intolerance to narcotics
  • Simultaneous lumbar diskectomy and a fusion technique
  • Known renal failure
  • Pregnancy
  • Contraindications to Amitriptyline or Gabapentin prescription
  • Unable to use PCA
  • Habitual use of alcohol or opium
  • History of analgesic consumption during the last 24hours

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Tabriz University of Medical Sciences

Tabriz, East Azerbayjan, 5166614756, Iran

RECRUITING

MeSH Terms

Conditions

Intervertebral Disc Displacement

Interventions

GabapentinAmitriptyline

Condition Hierarchy (Ancestors)

Spinal DiseasesBone DiseasesMusculoskeletal DiseasesHerniaPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

AminesOrganic Chemicalsgamma-Aminobutyric AcidAminobutyratesButyratesAcids, AcyclicCarboxylic AcidsCyclohexanecarboxylic AcidsAcids, CarbocyclicCyclohexanesCycloparaffinsHydrocarbons, AlicyclicHydrocarbons, CyclicHydrocarbonsAmino AcidsAmino Acids, Peptides, and ProteinsDibenzocycloheptenesBenzocycloheptenesPolycyclic Aromatic HydrocarbonsHydrocarbons, AromaticPolycyclic Compounds

Study Officials

  • Dawood Aghamohammadi, MD

    Tabriz University

    STUDY CHAIR
  • Payman Vahedi, MD

    Tabriz University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dawood Aghamohammadi, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

November 14, 2009

First Posted

November 17, 2009

Study Start

May 1, 2009

Primary Completion

February 1, 2010

Study Completion

March 1, 2010

Last Updated

November 17, 2009

Record last verified: 2009-11

Locations